What was studied?
SURMOUNT-1 assigned 2,539 adults to tirzepatide study groups or placebo for 72 weeks. Participants had obesity, or overweight with a weight-related complication, and did not have diabetes.
What did the researchers report?
Average weight reduction was greater in the tirzepatide groups than with placebo. Gastrointestinal events were the most common adverse effects; some participants stopped treatment because of adverse events.
What are the limits?
The findings apply to the studied pharmaceutical regimens and eligibility criteria. They do not establish universal outcomes, indefinite durability or equivalence between a clinical study product and catalog materials.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.